Industry group release testing recommendations for oligonucleotide-based therapeutics

July 8, 2014
Credit: 2014, Mary Ann Liebert, Inc., publishers

Novel oligonucleotide-based drugs in development offer promising alternatives for treating a range of diseases. A group of industry and regulatory scientists developing these new nucleic acid-based therapies released consensus recommendations for evaluating the pharmacological safety of oligonucleotide therapeutics. The document is published in Nucleic Acid Therapeutics.

Cindy Berman and coauthors from Pfizer Pharmaceuticals, GlaxoSmithKline, Preclinsight, Merck Sharp & Dohme Corp., Tepper Nonclinical Consulting, and Isis Pharmaceuticals provide the consensus opinion of the Safety Pharmacology Subcommittee of the Oligonucleotide Safety Working Group in the article "Recommendations for Safety Pharmacology Evaluations of Oligonucleotide-Based Therapeutics." The recommendations emphasize in particular the importance of safety pharmacology studies to evaluate the potential effects of systemically administered oligonucleotide-based drugs on cardiovascular function.

"It is our hope that during this period of rapid advancement both regulators and researchers alike will recognize and benefit from these carefully considered safety testing ," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.

Explore further: Drug delivery strategy eliminates myotonia symptoms in mice with myotonic dystrophy

More information: The article is available on the Nucleic Acid Therapeutics website.

Related Stories

Can toxicity of a DNA drug be predicted and minimized?

August 27, 2013

New classes of therapeutic antisense oligonucleotides can have toxic effects on the liver. A novel machine learning-based approach used to predict the hepatotoxic potential of an antisense drug based on its chemical sequence ...

Recommendations issued to prevent VTE in maternal patients

December 11, 2013

(HealthDay)—The Physician-Patient Alliance for Health & Safety, the Institute for Healthcare Improvement, and the National Perinatal Association have developed safety recommendations aimed at preventing venous thromboembolism ...

RNA aptamers targeted to plasminogen activator inhibitor

June 19, 2014

Plasminogen activators are proteins involved in the breakdown of blood clots, and an elevated level of plasminogen activator inhibitor-1 (PAI-1) is associated with an increased risk for clotting and cardiovascular disease. ...

Recommended for you

Sustaining biomedical research: Med school deans speak out

May 27, 2015

Cuts in federal support and unreliable funding streams are creating a hostile work environment for scientists, jeopardizing the future of research efforts and ultimately clinical medicine, according to leaders of the nation's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.